NCT01482962 · OUTCOME

Plasma Concentration-time Data to Contribute to Future Population Pharmacokinetics (PK) Analysis

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma · Source last updated 2018-07-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Cycle 1, Days 1 and 7; Cycle 2, Day 8; Cycle 3, Day 8; Cycle 4, Day 8. Duration is approximately 4 months.

Analysis population: This Outcome Measure was registered in error and is not a Primary or Secondary Outcome Measure.

Groups in this outcome

Alisertib 50 mg, enteric-coated tablet formulation, orally, twice daily for 7 consecutive days (Cycle Days 1-7) in a 21-day cycle (Up to 148 Weeks).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Alisertib	0

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

groups

population Description

This Outcome Measure was registered in error and is not a Primary or Secondary Outcome Measure.

reporting Status

POSTED

time Frame

Cycle 1, Days 1 and 7; Cycle 2, Day 8; Cycle 3, Day 8; Cycle 4, Day 8. Duration is approximately 4 months.

title

Plasma Concentration-time Data to Contribute to Future Population Pharmacokinetics (PK) Analysis

type

SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice